Pilot Study of Incidence of Major Adverse Cardiac Events and Effectiveness of Stent Delivery after Intravascular Lithotripsy Catheter Balloon for Calcified Coronary Artery in Adults

Mackay Hospital and Health Service0 个研究点目标入组 10 人开始时间: 2021年6月7日最近更新: 2022年11月14日

适应症

试验速览

暂无简介。

•Troponin must be less than or equal to the upper limit of lab normal value within 24 hours prior to the procedure or if troponin is elevated, concomitant CK must be normal
•The target vessel must have a TIMI flow 3 at baseline
•Patients with significant (> 50% diameter stenosis) native coronary artery disease including stable or unstable angina and silent ischemia, suitable for PCI
•Ability to tolerate dual antiplatelet agent (i.e. aspirin, clopidogrel, prasugrel, or ticagrelor for 1 year and single antiplatelet therapy for life
•Single lesion stenosis of protected LMCA, or LAD, RCA or LCX artery > 50% in a reference vessel of 2.5mm – 4.0 mm diameter and < 32 mm length
•Presence of calcification within the lesion on both sides of the vessel as assessed by angiography
•Planned treatment of single lesion in one vessel
•Ability to pass a 0.014’’ guide wire across the lesion
•Patient, or authorized representative, signs a written Informed Consent form to participate in the study, prior to any study-mandated procedures
•Patient is able and willing to comply with all assessments in the study

•Concomitant use of other techniques to deal CAC such as atherectomy and special balloons
•Severe renal failure
•Severe anaemia
•Previous PCI within 30 days of planned procedure
•Patients not suitable for consenting such as severe memory impairment
•Acute coronary syndrome within 1 month from planned procedure
•Severe Heart Failure (NYHA III or IV)
•Unable to tolerate dual antiplatelet agents (Aspirin + clopidogrel or ticargrelor or prasugrel) for 1 year for any reason
•Contrast allergy
•Active infection

发起方